REGULATORY
Re-Pricing Rule for “Huge-Seller” Drugs Necessary Compromise to Protect Universal Healthcare While Promoting Innovation: Health Minister
Health Minister Yasuhisa Shiozaki asked the pharmaceutical industry to understand the need for the new re-pricing rule for huge-seller drugs in a recent interview with Jiho. The rule, which will be introduced in the next NHI price revision, “was a…
To read the full story
REGULATORY
- MHLW Drafts Guideline Update, Urges Makers to Factor Distribution Costs into WPPs
December 16, 2025
- MHLW to Add Company-Driven Route to “Specific-Use Drug” Designations
December 16, 2025
- MHLW Council Determines 3 “Drug Loss” Products as High-Need, to Seek Development
December 16, 2025
- LDP Biosimilar Group Submits Request to Finance Minister, Seeks Continued Support
December 16, 2025
- LDP’s Patch League Urges Finance Minister to Continue Coverage, Support Prices
December 16, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





